Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging
Abstract Cancer-Associated Fibroblasts (CAFs) represent the most prominent component of
the tumor microenvironment (TME). Recent studies demonstrated that CAF are …
the tumor microenvironment (TME). Recent studies demonstrated that CAF are …
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma
E Hasanov, DN Yeboa, MD Tucker… - CA: A Cancer …, 2022 - Wiley Online Library
Brain metastases are a challenging manifestation of renal cell carcinoma. We have a limited
understanding of brain metastasis tumor and immune biology, drivers of resistance to …
understanding of brain metastasis tumor and immune biology, drivers of resistance to …
[HTML][HTML] Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review
LS Ter Maat, IAJ van Duin, SG Elias… - European Journal of …, 2022 - Elsevier
Background Checkpoint inhibition has radically improved the perspective for patients with
metastatic cancer, but predicting who will not respond with high certainty remains difficult …
metastatic cancer, but predicting who will not respond with high certainty remains difficult …
Preparation and Bioevaluation of 18F-Labeled Small-Molecular Radiotracers via Sulfur(VI) Fluoride Exchange Chemistry for Imaging of Programmed Cell Death …
X Hu, G Lv, D Hua, N Zhang, Q Liu, S Qin… - Molecular …, 2023 - ACS Publications
Nowadays, one of the most effective methods of tumor immunotherapy is blocking
programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) …
programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) …
[HTML][HTML] Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
E Lopci - Journal of Clinical Medicine, 2021 - mdpi.com
Immunotherapy with checkpoint inhibitors has prompted a major change not only in cancer
treatment but also in medical imaging. In parallel with the implementation of new drugs …
treatment but also in medical imaging. In parallel with the implementation of new drugs …
Preclinical and first-in-human evaluation of 18F-labeled D-peptide antagonist for PD-L1 status imaging with PET
M Zhou, X Wang, B Chen, S Xiang, W Rao… - European Journal of …, 2022 - Springer
Abstract Purpose PD-L1 PET imaging allows for the whole body measuring its expression
across primary and metastatic tumors and visualizing its spatiotemporal dynamics before …
across primary and metastatic tumors and visualizing its spatiotemporal dynamics before …
[HTML][HTML] Skin cancer pathobiology at a glance: a focus on imaging techniques and their potential for improved diagnosis and surveillance in clinical cohorts
EG Dobre, M Surcel, C Constantin, MA Ilie… - International Journal of …, 2023 - mdpi.com
Early diagnosis is essential for completely eradicating skin cancer and maximizing patients'
clinical benefits. Emerging optical imaging modalities such as reflectance confocal …
clinical benefits. Emerging optical imaging modalities such as reflectance confocal …
[HTML][HTML] Protein scaffolds: antibody alternatives for cancer diagnosis and therapy
R Luo, H Liu, Z Cheng - RSC chemical biology, 2022 - pubs.rsc.org
Although antibodies are well developed and widely used in cancer therapy and diagnostic
fields, some defects remain, such as poor tissue penetration, long in vivo metabolic …
fields, some defects remain, such as poor tissue penetration, long in vivo metabolic …
[HTML][HTML] Molecular imaging to support cancer immunotherapy
PP van de Donk, SF Oosting, DG Knapen… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
The advent of immune checkpoint inhibitors has reinvigorated the field of immuno-oncology.
These monoclonal antibody-based therapies allow the immune system to recognize and …
These monoclonal antibody-based therapies allow the immune system to recognize and …
[HTML][HTML] Recent advancement of PD-L1 detection technologies and clinical applications in the era of precision cancer therapy
Y Zhang, J Wu, C Zhao, S Zhang, J Zhu - Journal of Cancer, 2023 - ncbi.nlm.nih.gov
Programmed death-1 is a protein found on the surface of immune cells that can interact with
its ligand, programmed death-ligand 1 (PD-L1), which is expressed on the plasma …
its ligand, programmed death-ligand 1 (PD-L1), which is expressed on the plasma …